Amgen Stock Sinks On Modest Obesity Drug Results, But Retail Sentiment Remains Steady

Barchart · 11/26 08:18
Amgen’s weight-loss drug candidate MariTide is meant to be administered subcutaneously monthly or less frequently in obese or overweight patients without Type 2 diabetes.